S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

PSTX Poseida Therapeutics Inc

2.705

-0.105 (-3.74%)

Last Updated: 02:09:40

Delayed by 15 minutes

Biotech Soars on Research Collaboration And License Agreement Release

A California-based biotech company is turning heads on Wednesday after it announced that it entered into a research collaboration and license agreement with Astellas...

To read the full story on AllPennyStocks.com, click here.

Poseida Therapeutics (NASDAQ:PSTX)
Historical Stock Chart
From May 2024 to Jun 2024

Click Here for more Poseida Therapeutics Charts.

Poseida Therapeutics (NASDAQ:PSTX)
Historical Stock Chart
From Jun 2023 to Jun 2024

Click Here for more Poseida Therapeutics Charts.

Poseida Therapeutics Inc News

Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
Tuesday 4 June 2024 (2 weeks ago) • PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 15 May 2024 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 15 May 2024 (1 month ago) • Edgar (US Regulatory)

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
Wednesday 15 May 2024 (1 month ago) • PR Newswire (US)

Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting
Thursday 9 May 2024 (1 month ago) • PR Newswire (US)

Form EFFECT - Notice of Effectiveness
Monday 6 May 2024 (1 month ago) • Edgar (US Regulatory)

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Thursday 2 May 2024 (2 months ago) • PR Newswire (US)

Biotech Soars on Research Collaboration And License Agreement Release
Thursday 2 May 2024 (2 months ago) • AllPennyStocks.com

Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Wednesday 1 May 2024 (2 months ago) • PR Newswire (US)

Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
Thursday 18 April 2024 (2 months ago) • PR Newswire (US)

Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
Wednesday 17 April 2024 (2 months ago) • PR Newswire (US)

Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
Tuesday 9 April 2024 (2 months ago) • PR Newswire (US)

More Poseida Therapeutics Inc News Articles

Australian SE All Ordina...

National Australia Bank

Sterling vs AUD

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions